09/22/23 8:00 AMNasdaq : RYTM high shortRhythm Pharmaceuticals Presents New Data at ESPE 2023Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathwayRHEA-AIneutral
09/19/23 8:01 AMNasdaq : RYTM acquisitionclinical trialhigh shortRhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic ObesityRhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathwayRHEA-AIneutral
09/08/23 4:01 PMNasdaq : RYTM high shortRhythm Pharmaceuticals Announces New Employment Inducement GrantsRhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathwayRHEA-AIneutral
09/08/23 7:59 AMNasdaq : RYTM high shortRhythm Pharmaceuticals Announces Update to September Conference ParticipationRhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathwayRHEA-AInegative
09/06/23 7:59 AMNasdaq : RYTM high shortRhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl SyndromeRhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transformingRHEA-AIneutral
08/28/23 8:00 AMNasdaq : RYTM conferenceshigh shortRhythm Pharmaceuticals to Present at Investor Conferences in SeptemberRhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathwayRHEA-AInegative
08/07/23 8:00 AMNasdaq : RYTM high shortRhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France Rhythm Pharmaceuticals,RHEA-AIneutral
08/04/23 4:01 PMNasdaq : RYTM high shortRhythm Pharmaceuticals Announces New Employment Inducement GrantsRhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathwayRHEA-AIneutral
08/01/23 7:00 AMNasdaq : RYTM earningshigh shortRhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business UpdateAchieved commercial salesRHEA-AIneutral
07/19/23 8:00 AMNasdaq : RYTM high shortRhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl SyndromeRhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their familiesRHEA-AInegative